{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:13:58Z","timestamp":1786407238009,"version":"build-2736575974"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Spanish Society of Ocular Inflammation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.semarthrit.2020.08.010","type":"journal-article","created":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T11:14:21Z","timestamp":1598613261000},"page":"1299-1306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review"],"prefix":"10.1016","volume":"50","author":[{"given":"Alejandro","family":"G\u00f3mez-G\u00f3mez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Est\u00edbaliz","family":"Loza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa Piedad","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M Garc\u00eda Ruiz","family":"de Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Mu\u00f1oz-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Rodr\u00edguez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Cordero-Coma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5-6","key":"10.1016\/j.semarthrit.2020.08.010_bib0001","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/BF00163549","article-title":"The natural history of uveitis","volume":"14","author":"Nussenblatt","year":"1990","journal-title":"Int Ophthalmol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.08.010_bib0002","doi-asserted-by":"crossref","first-page":"705","DOI":"10.5301\/ejo.5000278","article-title":"Review on the Worldwide epidemiology of uveitis","volume":"23","author":"Miserocchi","year":"2013","journal-title":"Eur J Ophthalmol."},{"issue":"9","key":"10.1016\/j.semarthrit.2020.08.010_bib0003","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/bjo.2003.037226","article-title":"Degree, duration, and causes of visual loss in uveitis","volume":"88","author":"Durrani","year":"2004","journal-title":"Br J Ophthalmol."},{"issue":"4","key":"10.1016\/j.semarthrit.2020.08.010_bib0004","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.reuma.2015.08.004","article-title":"Burden and direct costs of non infectious uveitis in Spain","volume":"12","author":"Ad\u00e1n-Civera","year":"2016","journal-title":"Reumatol Cl\u00ednica Engl Ed"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.08.010_bib0005","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.1111\/aos.12987","article-title":"Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis","volume":"94","author":"Thorne","year":"2016","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.08.010_bib0006","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1509852","article-title":"Adalimumab in patients with active noninfectious uveitis","volume":"375","author":"Jaffe","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/09273948.2016.1237663","article-title":"Short-term intensive immunosuppression: a randomized, three-arm study of intravenous pulse methylprednisolone and cyclophosphamide in macular serpiginous choroiditis","volume":"26","author":"Venkatesh","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.08.010_bib0008","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular Inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0009","unstructured":"Hwang YG, Saag K.The safety of low-dose glucocorticoids in rheumatic diseases.:9."},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0010","unstructured":"Smits NAM, Duru N, Bijlsma JWJ, Jacobs JWG. Adverse events of intravenous glucocorticoid pulse therapy in inflammatory diseases: a meta-analysis.:8."},{"issue":"12","key":"10.1016\/j.semarthrit.2020.08.010_bib0011","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.ophtha.2017.06.017","article-title":"Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis","volume":"124","author":"Suhler","year":"2017","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.08.010_bib0012","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0002-9394(14)74795-6","article-title":"Combined use of cyclosporine and ketoconazole in the treatment of endogenous uveitis","volume":"113","author":"de Smet","year":"1992","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.08.010_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.semarthrit.2010.05.008","article-title":"Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis","volume":"40","author":"Pato","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.08.010_bib0014","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.ophtha.2011.12.030","article-title":"A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis","volume":"119","author":"Lee","year":"2012","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0015","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study): rituximab in ocular lesions of Behcet\u2019s disease","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.08.010_bib0016","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/09273948.2016.1231331","article-title":"Efficacy of anti-IL6-receptor tocilizumab in refractory cystoid macular edema of birdshot retinochoroidopathy report of two cases and literature review","volume":"25","author":"Calvo-R\u00edo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"issue":"42","key":"10.1016\/j.semarthrit.2020.08.010_bib0017","doi-asserted-by":"crossref","first-page":"e8045","DOI":"10.1097\/MD.0000000000008045","article-title":"Efficacy and safety of immunomodulatory drugs in patients with anterior uveitis: a systematic literature review","volume":"96","author":"G\u00f3mez-G\u00f3mez","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.08.010_bib0018","first-page":"552","article-title":"Documento de recomendaciones de tratamiento de la uve\u00edtis anterior no infecciosa","volume":"149","author":"Espinosa","year":"2017","journal-title":"Med Cl\u00ednica"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.08.010_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0020","unstructured":"Ozyazgan Y, Yurdakul S, Yazici H, et\u00a0al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behqet's syndrome: a single masked trial.:3."},{"issue":"10050","key":"10.1016\/j.semarthrit.2020.08.010_bib0021","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.08.010_bib0022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/bjo.74.6.344","article-title":"Cyclosporin in the treatment of severe chronic idiopathic uveitis","volume":"74","author":"de Vries","year":"1990","journal-title":"Br J Ophthalmol."},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0023","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0002-9394(14)76692-9","article-title":"Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis","volume":"112","author":"Nussenblatt","year":"1991","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.08.010_bib0024","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1001\/archopht.123.5.634","article-title":"Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis","volume":"123","author":"Murphy","year":"2005","journal-title":"Arch Ophthalmol."},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0025","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0002-9394(14)71454-0","article-title":"A Masked, randomized, dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfectious origin","volume":"115","author":"Nussenblatt","year":"1993","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.08.010_bib0026","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","article-title":"A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis","volume":"121","author":"Rathinam","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0027","first-page":"509","article-title":"Results of the first international workshop","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0028","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ajo.2016.06.004","article-title":"Outcomes of Vogt-Koyanagi-Harada disease: a subanalysis from a randomized clinical trial of antimetabolite therapies","volume":"168","author":"Shen","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0029","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.ajo.2013.05.002","article-title":"Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial","volume":"156","author":"Mackensen","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0030","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ajo.2017.03.001","article-title":"Interferon-alpha2a and systemic corticosteroid in monotherapy in chronic uveitis: results of the randomized controlled BIRDFERON study","volume":"177","author":"Fardeau","year":"2017","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.08.010_bib0031","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.08.010_bib0032","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0033","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/09273940701299370","article-title":"A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to beh\u00e7et's disease","volume":"15","author":"Buggage","year":"2007","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0034","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ophtha.2018.09.044","article-title":"Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU)","volume":"126","author":"Heissigerov\u00e1","year":"2019","journal-title":"Ophthalmology"},{"issue":"9121","key":"10.1016\/j.semarthrit.2020.08.010_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0140-6736(05)79515-5","article-title":"Rescue therapy with mycophenolate mofetil in refractory uveitis","volume":"352","author":"Kilmartin","year":"1998","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0036","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/archopht.1978.03910050115002","article-title":"Immunosuppressive therapy for severe chronic uveitis","volume":"96","author":"Andrasch","year":"1978","journal-title":"Arch Ophthalmol."},{"issue":"8","key":"10.1016\/j.semarthrit.2020.08.010_bib0037","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0161-6420(02)01097-7","article-title":"Successful treatment of serpiginous choroiditis with alkylating agents","volume":"109","author":"Akpek","year":"2002","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.08.010_bib0038","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/112067210701700110","article-title":"Long-term follow-up of tacrolimus treatment in immune posterior uveitis","volume":"17","author":"Figueroa","year":"2007","journal-title":"Eur J Ophthalmol"},{"issue":"5","key":"10.1016\/j.semarthrit.2020.08.010_bib0039","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3109\/09273948.2010.501132","article-title":"Pars plana vitrectomy versus immunomodulatory therapy for intermediate uveitis: a prospective, randomized pilot study","volume":"18","author":"Quinones","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.08.010_bib0040","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ajo.2009.05.008","article-title":"Azathioprine for ocular inflammatory diseases","volume":"148","author":"Pasadhika","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.08.010_bib0041","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(99)90011-8","article-title":"Methotrexate treatment for sarcoid-associated panuveitis","volume":"106","author":"Dev","year":"1999","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.08.010_bib0042","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/bjo.57.9.706","article-title":"Long-lasting remission of Behcet's disease after chlorambucil therapy","volume":"57","author":"Abdalla","year":"1973","journal-title":"Br J Ophthalmol."},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0043","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0002-9394(74)90229-3","article-title":"The use of chlorambucil in intractable idiopathic uveitis","volume":"78","author":"Godfrey","year":"1974","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"10.1016\/j.semarthrit.2020.08.010_bib0044","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/imj.14215","article-title":"The use of biologic agents in the management of uveitis","volume":"49","author":"Trivedi","year":"2019","journal-title":"Intern Med J"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.08.010_bib0045","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.ajo.2008.09.010","article-title":"Infliximab effects compared to conventional therapy in the management of retinal vasculitis in beh\u00e7et disease","volume":"146","author":"Tabbara","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.08.010_bib0046","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following Certolizumab Pegol treatment in patients with axial spondyloarthritis: CZP and uveitis in axial SpA","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09273948.2014.967779","article-title":"Certolizumab Pegol, a new anti-TNF-\u03b1 in the armamentarium against ocular inflammation","author":"Lloren\u00e7","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.08.010_bib0048","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1016\/j.ophtha.2011.05.019","article-title":"Golimumab for uveitis","volume":"118","author":"Cordero-Coma","year":"2011","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0049","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/09273948.2012.741744","article-title":"Beh\u00e7et disease-associated uveitis successfully treated with golimumab","volume":"21","author":"Mesquida","year":"2013","journal-title":"Ocul Immunol Inflamm"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0050","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/09273948.2013.844265","article-title":"Long-term treatment with golimumab for severe uveitis","volume":"22","author":"Miserocchi","year":"2014","journal-title":"Ocul Immunol Inflamm"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.08.010_bib0051","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.semarthrit.2016.03.002","article-title":"Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients","volume":"46","author":"Calvo-R\u00edo","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/717598","article-title":"Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience","volume":"2014","author":"Cordero-Coma","year":"2014","journal-title":"Mediators Inflamm"},{"issue":"1","key":"10.1016\/j.semarthrit.2020.08.010_bib0053","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10792-016-0239-y","article-title":"Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis","volume":"37","author":"Yazgan","year":"2017","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.semarthrit.2020.08.010_bib0054","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0055","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","article-title":"New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases","volume":"41","author":"Wendling","year":"2011","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2020.08.010_bib0056","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1002\/art.22918","article-title":"Do tumor necrosis factor inhibitors cause uveitis? A registry-based study","volume":"56","author":"Lim","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0057","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Beh\u00e7et's disease","volume":"26","author":"Abu El-Asrar","year":"2006","journal-title":"Int Ophthalmol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0058","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American collaborative retina study group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.semarthrit.2020.08.010_bib0059","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.ophtha.2014.06.050","article-title":"Long-term effects of tocilizumab therapy for refractory uveitis-related macular edema","volume":"121","author":"Mesquida","year":"2014","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.08.010_bib0060","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1001\/archophthalmol.2010.205","article-title":"Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis","volume":"128","author":"Parodi","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.010_bib0061","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1089\/jop.2009.0093","article-title":"Intravitreal bevacizumab versus triamcinolone acetonide for refractory uveitic cystoid macular edema: a randomized pilot study","volume":"26","author":"Soheilian","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2020.08.010_bib0062","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/jop.2009.0089","article-title":"Intravitreal ranibizumab in the treatment of cystoid macular edema associated with retinitis pigmentosa","volume":"25","author":"Artunay","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0063","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","article-title":"Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis","volume":"117","author":"Pavesio","year":"2010","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.semarthrit.2020.08.010_bib0064","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/bjo.2006.092965","article-title":"The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study","volume":"90","author":"Tranos","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2147\/OPTH.S198401","article-title":"Outcomes of treatment with sirolimus for non-infectious uveitis: a meta-analysis and systematic review","volume":"13","author":"Cabahug","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.010_bib0066","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","article-title":"Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration","volume":"33","author":"Bianchi","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.semarthrit.2020.08.010_bib0067","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10792-019-01183-9","article-title":"Ocular manifestations of rheumatic diseases","volume":"40","author":"Kemeny-Beke","year":"2020","journal-title":"Int Ophthalmol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:04:06Z","timestamp":1758733446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0049017220302407"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.010","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of immunomodulatory drugs in patients with non-infectious intermediate and posterior uveitis, panuveitis and macular edema: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}